Equity Profile

CAI

Caris Life Sciences, Inc.

Health CareBiotechnology$6.3B

Feb15Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced genomic testing services to help guide treatment decisions for cancer patients....

Key Metrics to Watch

Revenue Growth

Understanding revenue growth is essential as it reflects the company's ability to expand its market presence and demand for its genomic testing services.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and financial health, providing insight into how well the company is managing its expenses relative to its revenue.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced genomic testing services to help guide treatment decisions for cancer patients. Operating in the health care sector, the company plays a crucial role in the growing trend toward personalized medicine, which aims to tailor treatments based on individual genetic profiles.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris Life Sciences reported an EPS of $0.00, exceeding expectations by 100%. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Focus on expanding genomic testing capabilities.
Commitment to enhancing partnerships with healthcare providers.
Plans to invest in research and development for new testing technologies.

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Caris Life Sciences's upcoming earnings report, given its history of beating EPS estimates. However, uncertainty remains regarding revenue growth and market conditions.

Bull Case

If Caris continues its trend of exceeding EPS expectations, it could signal strong operational efficiency and growing demand for its services, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to show substantial revenue growth or if test volumes decline, it could raise concerns about its market position and lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the growth rate in test volumes compared to last quarter?

This metric will indicate whether the company is successfully increasing its market share and meeting demand for its genomic testing services.

What guidance can management provide regarding future revenue expectations?

Future revenue guidance will be critical for investors to assess the company's growth trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Caris to significantly increase its test volumes due to expanding partnerships and new product offerings.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent trends in personalized medicine indicate a growing market that Caris is well-positioned to capitalize on.

Key Risk

If test volume growth exceeds 15%, it could challenge the consensus view of slowing demand.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around whether Caris can maintain its growth momentum in a competitive biotechnology landscape.

Bull Confirmed If

A test volume growth rate of over 15% quarter-over-quarter would confirm strong demand and operational success.

Bear Confirmed If

A decline in test volumes or negative revenue guidance would signal potential issues in market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations and raises guidance, history suggests the stock could rise by around 0.82% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see little movement as investors digest the commentary.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.32%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new partnerships with healthcare providers.
2Details on any new testing technologies being introduced.
3Management's outlook on the competitive landscape in biotechnology.
4Specific numbers on test volume growth compared to previous quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Scorpio Tankers Inc.

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced genomic testing services to help guide treatment decisions for cancer patients....

Key Metrics to Watch

Revenue Growth

Understanding revenue growth is essential as it reflects the company's ability to expand its market presence and demand for its genomic testing services.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and financial health, providing insight into how well the company is managing its expenses relative to its revenue.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris Life Sciences reported an EPS of $0.00, exceeding expectations by 100%. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Focus on expanding genomic testing capabilities.
Commitment to enhancing partnerships with healthcare providers.
Plans to invest in research and development for new testing technologies.

Expectations

Wall Street Expectations

Bull Case

If Caris continues its trend of exceeding EPS expectations, it could signal strong operational efficiency and growing demand for its services, leading to a significant stock price increase.

Bear Case

Conversely, if the company fails to show substantial revenue growth or if test volumes decline, it could raise concerns about its market position and lead to a negative reaction in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the growth rate in test volumes compared to last quarter?

This metric will indicate whether the company is successfully increasing its market share and meeting demand for its genomic testing services.

What guidance can management provide regarding future revenue expectations?

Future revenue guidance will be critical for investors to assess the company's growth trajectory and overall health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Caris to significantly increase its test volumes due to expanding partnerships and new product offerings.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent trends in personalized medicine indicate a growing market that Caris is well-positioned to capitalize on.

Key Risk

If test volume growth exceeds 15%, it could challenge the consensus view of slowing demand.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around whether Caris can maintain its growth momentum in a competitive biotechnology landscape.

Bull Confirmed If

A test volume growth rate of over 15% quarter-over-quarter would confirm strong demand and operational success.

Bear Confirmed If

A decline in test volumes or negative revenue guidance would signal potential issues in market demand.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations and raises guidance, history suggests the stock could rise by around 0.82% on the following day, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may see little movement as investors digest the commentary.

Miss

Should the company miss expectations, history suggests a potential decline of around 6.32%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new partnerships with healthcare providers.
2Details on any new testing technologies being introduced.
3Management's outlook on the competitive landscape in biotechnology.
4Specific numbers on test volume growth compared to previous quarters.